Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection

Digestive Diseases and Sciences

Volumn 50, Issue 10, 2005, Pages 1793-1803

  Wright, Harlan ^a   Alex, Philip ^b,c   Nguyen, Thuan ^b   Bader, Teddy ^a   Gurakar, Ahmet ^a   Sebastian, Anthony ^a   Gonzales, Liberty ^b   Wallis, Gemma ^b   Naylor, Mark ^b,c   Dozmorov, Igor ^b   Centola, Michael ^b,c   Nour, Bakr ^a  

^a INTEGRIS BAPTIST MEDICAL CENTER   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemokines; Cytotoxic and humoral cytokines; Pegylated interferon ribavirin

Indexed keywords

ALPHA2B INTERFERON; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RIBAVIRIN;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CLUSTER ANALYSIS; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 26444465144     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2940-y     Document Type: Article

References (40)

1. World Health Organization: Hepatitis C. Wkly Epidemiol Rec 72:65-69, 1997
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562, 1999
3. Alter MJ: Epidemiology of hepatitis C. Hepatology 26:62S-65S, 1997
4. Hoofnagle JH: Course and outcome of hepatitis C. Hepatology 36(5; Suppl 1):S21-S29, 2002
5. Fattovich G, Giustina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:463-472, 1997
6. Bruix J, Barrera JM, Calvet X, et al.: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 2:1004-1006, 1989
7. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH: Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol 19:222-226, 1994
8. Cummings KJ, Lee SM, West ES, et al.: Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta- analysis of randomized trials. JAMA 285:193-199, 2001
9. McHutchison JG, Gordon SC, Schiff ER: Interferon-α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492, 1998
10. August-Jorg BS, Borovicka J, Dufour JF, et al.: Swiss Association for the Study of the Liver: Twenty-four vs. fourty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C. Swiss Med Wkly 23;133(33-34):455-460, 2003
11. McHutchison JG, Manns MP, Garaud JJ, Albrecht J: Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon-α 2b plus ribavirin. Gastroenterology 123:1061-1069, 2002
12. Fried MW, Shiffman ML, Reddy RK: Pegylated (40 kDa) interferon-α-2a (PEGASYS (R)) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. N Engl J Med 347:975-982, 2002
13. Mihm S, Fayyazi A, Hartmann H, Ramadori G: Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25(3):735-739, 1997
14. Batts KP, Ludwig J: Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19(12):1409-1417, 1995
15. Bertoletti A, Ferrari C: Kinetics of the immune response during HBV and HCV infection. Hepatology 38(1):4-13, 2003
16. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC: Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25:449-458, 1997
17. Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U: CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 159:1012-1018, 1997
18. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 24:759-765, 1996
19. Fan XG, Liu WE, Li CZ, et al.: Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection. Mediators Inflamm 7(4):295-297, 1998
20. Oxo Chemie Ag Initiates Macrokine Phase 2 Clinical Trials. Worldwide Biotech, August 2000
21. Simmonds P, Alberti A, Alter HJ, et al.: A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 19:1321-1324, 1994
22. Szodoray P, Alex P, Brun JG, Centola M, Jonsson R: Description of circulating cytokines in Sjögren's syndrome using a multiplex cytokine array system. Scand J Immunol 59(6):592-599, 2004
23. Chappell C, Wallis G, Alex P, et al.: Distinct immunopathological disease profiles of the spondyloarthropathies. FASEB J 18(3; Suppl), 2004 (abstr)
24. Alex P, Wallis G, Szodoray P, et al.: A powerful prognostic tool to predict treatment outcome in rheumatoid arthritis. Arth Rheum 29(9; Suppl):129, 2003 (abstr)
25. Chappell C, Scofield H, Wallis G, Kurien BT, Morris RI, Centola MB: Distinct molecular immunopathological disease profiles of ankylosing spondylitis. Arth Rheum 29(9; Suppl):1560, 2003 (abstr)
26. Dozmorov I, Centola M: An associative analysis of gene expression array data. Bioinformatics 22;19(2):204-211, 2003
27. Dozmorov IM, Saban MR, Knowlton N, Centola M, Saban R: Connective molecular pathways of experimental bladder inflammation. Physiol Genom 15:209-222, 2003
28. EASL International Consensus Conference on Hepatitis C. Paris, 26-27 February 1999. Consensus statement [no authors listed]. J Hepatol 31(Suppl 1):3-8, 1999
29. Heathcote EJ, Shiffman ML, Cooksley WG: Peginterferon-α-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673-1680, 2000
30. Davis GL, Esteban-Mur R, Rustgi V: Interferon-α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339:1493-1499, 1998
31. Olivieri I, Palazzi C, Padula A: Hepatitis C virus and arthritis. Rheum Dis Clin North Am 29(1):111-122, 2003
32. Aceti A, Taliani G, Sorice M, Amendolea MA: HCV and Sjogren's syndrome. Lancet 6;339(8806):1425-1426, 1992
33. Hirohata S, Inoue T, Ito K: Development of rheumatoid arthritis after chronic hepatitis caused by hepatitis C virus infection. Intern Med 31(4):493-495, 1992
34. Siegel LB, Cohn L, Nashel D: Rheumatic manifestations of hepatitis C infection. Semin Arth Rheum 23(3):149-154, 1993
35. Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH: Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol 163:6236-6243, 1999
36. Murai M, Yoneyama H, Harada A, et al.: Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 104:49-57, 1999
37. Westermann J, Bode U: Distribution of activated T cells migrating through the body: a matter of life and death. Immunol Today 20:302-306, 1999
38. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, Lemon SM, Lanford RE: Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78(24):13779-13792, 2004
39. Lichterfeld M, Leifeld L, Nischalke HD, Rockstroh JK, Hess L, Sauerbruch T, Spengler U: Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J Infect Dis 15;185(12):1803-1807, 2002
40. Lau C, Yam LY, Cheung TM, Poon E, Yung RW, Yuen KY: Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 10;361(9369):1615-1617, 2003